FINAL FINDINGS OF SCIENTIFIC MISCONDUCT NIH GUIDE, Volume 23, Number 30, August 12, 1994 P.T. 34 Keywords: Ethics/Values in Science & Technol Public Health Service Notice is hereby given that the Office of Research Integrity (ORI) has made final findings of scientific misconduct in the following cases: Anand Tewari, M.D., Stanford University. The Division of Research Investigations (DRI) of the Office of Research Integrity (ORI) conducted an investigation into possible scientific misconduct on the part of Dr. Tewari while a postdoctoral fellow in the Department of Surgery, Stanford University School of Medicine. ORI concluded that Dr. Tewari committed scientific misconduct in clinical research supported by an NIH grant by fabricating ophthalmologic examination results; fabricating and falsifying blood gas data; fabricating and falsifying values for glycerol determinations; falsifying standard errors and including fabricated data on platelet counts in a published article, \"Effects of interleukin-1 on platelet counts\" (The Lancet 336:712-714 (1990)), and related abstracts; and providing to his supervisors summaries of data that included falsified and fabricated data which were used in a PHS grant application. The published article containing the falsified and fabricated data was retracted on August 22, 1992. The Lancet 340:496. Dr. Tewari accepted the ORI findings and agreed to a Voluntary Exclusion and Settlement Agreement under which he may not apply for Federal grant or contract funds except for the non-research training or practice of clinical medicine, and may not serve on PHS advisory committees, boards, or peer review groups for a five-year period beginning March 1, 1994. Annmarie Surprenant, Ph.D., Glaxo Institute for Molecular Biology. An inquiry and investigation conducted by the Oregon Health Sciences University (OHSU) found that Annmarie Surprenant, Ph.D., had misrepresented her academic credentials in a grant application for Public Health Service (PHS) research funds. The OHSU found that Dr. Surprenant had falsely stated that she had earned an M.D. degree from the University of Illinois at Chicago in 1976. As a result of the OHSU investigation, Dr. Surprenant resigned from the OHSU faculty. During its oversight review of the OHSU report, the Office of Research Integrity (ORI) discovered that Dr. Surprenant had also falsely claimed to have earned an M.D. on two additional PHS research grant applications. Based upon the OHSU report, as well as the information obtained by ORI during its oversight review, ORI found that Dr. Surprenant engaged in scientific misconduct by falsely claiming to have earned an M.D. in three PHS research grant applications. Dr. Surprenant accepted the ORI finding and agreed to a Voluntary Exclusion and Settlement Agreement under which she will not apply for Federal grant or contract funds and will not serve on PHS advisory committees, boards, or peer review groups for a three-year period beginning June 8, 1994. Mark S. Chagnon, Sc.D., Molecular BioQuest, Inc. A report of the Office of Research Integrity (ORI) of its investigation into allegations of possible scientific misconduct made against Mark S. Chagnon found that he engaged in scientific misconduct by misrepresenting his academic credentials in five research grant applications submitted to the National Institutes of Health. ORI found that Dr. Chagnon falsely claimed to have completed undergraduate and graduate studies in chemistry at the Massachusetts Institute of Technology (MIT), Lowell University (Lowell Institute of Technology) and Northeastern University. ORI also concluded that Dr. Chagnon falsely claimed to have earned an M.S. degree in organic chemistry from MIT. Although he neither admits nor denies the ORI finding of scientific misconduct, Dr. Chagnon has agreed to a Voluntary Exclusion and Settlement Agreement under which he will not apply for Federal grant or contract funds and will not serve on PHS advisory committees, boards, or peer review groups for a three-year period beginning June 28, 1994. INQUIRIES The Office of Research Integrity will continue to publish findings of scientific misconduct as further cases are closed. For further information, contact: Director Division of Research Investigations Office of Research Integrity 5515 Security Lane, Suite 700 Rockville, MD 20852 Telephone: (301) 443-5330 .
